Breast Cancer

Questionnaire results from the first weeks of the coronavirus disease 2019 (COVID-19) pandemic show that breast cancer treatment delays happened more often for younger vs older women.

At diagnosis, approximately 6% of breast cancers are metastatic breast cancer (MBC), which although treatable is not curable. Experts predicted that 276,480 women and 2620 men would receive such a diagnosis in 2020.

Risks of all-cause mortality and breast cancer-specific mortality decreased when female patients followed a more anti-inflammatory diet after their diagnosis of postmenopausal invasive breast cancer.

The Adjuvant Platinum and Taxane in Triple-Negative Breast Cancer trial investigated this combination adjuvant treatment vs the standard-of-care anthracycline plus docetaxel among patients with operable disease.

The challenges of complying with payer mandates in biosimilars were discussed in a webinar sponsored by The American Journal of Managed Care® and The Center for Biosimilars®.

Screening women aged 40 to 49 years for breast cancer reduced mortality by 25% in the first 10 years compared with waiting until at age 50 years and older, which is the common practice in the United Kingdom.